Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy Ameliorates Nonalcoholic Fatty Liver Disease in Obese Type 2 Diabetic Mice
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is increasingly common among patients with type 2 diabetes mellitus (T2DM). The two conditions can act synergistically to produce adverse outcomes. However, the therapeutic options for patients with NAFLD and T2DM are currently limited. Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) have shown therapeutic potential for diabetes and hepatic disorders such as liver cirrhosis and fulminant hepatic failure. The present study is aimed at investigating the effect of human UC-MSCs on a mouse model of NAFLD and T2DM, characterized by obesity-induced hyperglycaemia, dyslipidaemia, hepatic steatosis, and liver dysfunction. Thirty-week-old male C57BL/6 db/db mice were infused with human UC-MSCs or phosphate-buffered saline (PBS) via the tail vein once a week for six weeks. Age-matched male C57BL/6 wild-type db/+ mice were used as controls. Body weight and random blood glucose were measured every week. One week after the sixth infusion, intraperitoneal glucose tolerance tests and insulin tolerance tests were performed and the blood and liver were harvested for biochemical and histopathological examinations. Quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR), immunofluorescence staining, and western blot were performed to monitor the expression of the lipid metabolism- and regulatory pathway-related genes. UC-MSC infusions significantly ameliorated hyperglycaemia, attenuated the elevation of hepatic transaminases, and decreased lipid contents, including triglyceride, total cholesterol, and low-density lipoprotein cholesterol. Moreover, histological lesions in the liver diminished markedly, as evidenced by reduced lipid accumulation and attenuated hepatic steatosis. Mechanistically, UC-MSCs were found to regulate lipid metabolism by increasing the expression of fatty acid oxidation-related genes and inhibiting the expression of lipogenesis-related genes, which were associated with the upregulation of the HNF4 α-CES2 pathway. Our results demonstrate that human UC-MSCs can ameliorate NAFLD and reverse metabolic syndrome in db/db mice. Thus, UC-MSCs may serve as a novel therapeutic agent for T2DM patients with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149 · cited 1×
“Moreover, prognosis for patients with concomitant NAFLD and T2DM is worsened on account of increased risk for a life-threatening sequel such as cardiovascular disease and hepatocellular carcinoma, highlighting the need for improved treatment options [6, 7].”
BackgroundGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 1×
“Global estimates indicate that about 500million people have obesity and are at risk of significant obesity-related morbidity [1].”
BackgroundHayhurst, G. P., Lee, Y.-H., Lambert, G., Ward, J. M., & Gonzalez, F. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.4.1393-1403.2001 · Cited by 1,107 · cited 1×
“Liverspecific conditional knockout of HNF4α in adult mice led to severe steatosis associated with disruption of VLDL secretion and misregulation of ApoB and MTTP expression [27, 44].”
BackgroundZhang, Z., Lin, H., Shi, M., Xu, R., Fu, J., Lv, J., Chen, L., Lv, S., Li, Y., Yu, S., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07024.x · Cited by 372 · cited 1×
“In liver diseases, UC-MSCs have been demonstrated to exert therapeutic effects on decompensated liver cirrhosis [11, 12], liver failure [13], chemical-induced liver injury [14, 15], and autoimmune liver diseases such as primary biliary cholangitis [16].”
BackgroundSelf-citationManagement of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
Sahai, A., Malladi, P., Pan, X., Paul, R., Melin-Aldana, H., Green, R. M., & Whitington, P. F. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00199.2004 · Cited by 290 · cited 1×
“Interestingly, it is reported that when fed methionine-choline-deficient (MCD) diet for several weeks, db/db mice can develop NASH characterized by pronounced histological inflammation and fibrosis in the liver [38, 39].”
Background
Cited by
Abbaszadeh, H., Ghorbani, F., Derakhshani, M., Movassaghpour, A., & Yousefi, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29004 · Cited by 188
“They reported that these EVs alleviated SNFH in rats, whose mechanism might be associated with the elevation of VEGF and bone morphogenetic protein‐2 (BMP‐2).”
BackgroundInfluentialCurrent understanding of mesenchymal stem cells in liver diseases
Wu, M.-C., & Meng, Q.-H. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i9.1349 · Cited by 29
Zhao, N., Gao, Y.-F., Bao, L., Lei, J., An, H.-X., Pu, F.-X., Cheng, R.-P., Chen, J., Ni, H., Sui, B.-D., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02467-7 · Cited by 16
Hu, R., Zhao, J., Cheng, Y., Su, W., Ren, R., Zhang, H., Zhang, Y., Wang, A., Mu, Y., & Yu, S. (2025) · Stem Cells International · doi:10.1155/sci/4639115 · Cited by 7
“In recent years, the therapeutic potential of UC-MSCs has been explored in NAFLD [16], effectively improving carbohydrate and lipid metabolism.”
Self-citation
Metadata
- Authors
- Li, B., Cheng, Y., Yu, S., Zang, L., Yin, Y., Liu, J., Zhang, L., & Mu, Y.
- Venue
- Stem Cells International
- Publisher
- Wiley
- Published
- 2019-11-03
- Volume
- 2019
- Pages
- 1-12
- ISSN
- 1687-966X (ISSN-L)
- 1687-9678
- OpenAlex
- W2989387075
- Cited by
- 58
- References
- 6
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.